natgillin/translations-raw huggingface dataset:
The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the disclosure, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this disclosure. 
Uporaba spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima.
wherein heteroaryl is optionally substituted with one to two substituents independently selected from the group consisting of fluoro, chloro, bromo, and trifluoromethyl; 
ciklopropil opciono supstituiran sa jednim do dva fluoro supstituenta, ii) trifluorometil, ili iii) heteroaril izabran iz grupe koju čine tienil, furanil, tiazolil, izotiazolil, oksazolil, pirolil, i izoksazolil;
A pharmaceutical composition comprising a monodisperse composition for use as a medicament of any one of claims 1-10, and a pharmaceutically acceptable excipient. 
Farmaceutska smjesa, naznačena time, što sadrži monodisperznu smjesu iz bilo kojeg od zahtjeva 1-7 i farmaceutski prihvatljivi ekscipijent.
an antisense oligomer which has a nucleotide sequence having at least 90% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene. 
(3) antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 90% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 1 ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
A pharmaceutical composition comprising the antibody or antibody fragment thereof of any one of claims 1 to 6 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time da sadrži bispecifično antitijelo ili njegov bispecifični fragment antitijela prema bilo kojem zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač.
means (702-0) for encoding data of the at least one baseband frame by a Low Density Parity Check, LDPC, scheme; 
Kabelski predajnik iz patentnog zahtjeva 5, nadalje obuhvaća: sredstvo (209) za nasumično kodiranje servisnih podataka koji imaju najmanje jedno zaglavlje osnovnog frekvencijskog pojasa.
The system according to claim 1, wherein the liquid supply assembly further comprises a recirculation valve (78) to facilitate charging the pump and to maintain the manifold and the liquid supply container at ambient pressure during operation. 
Sustav prema zahtjevu 1, naznačen time da sklop za napajanje tekućinom nadalje sadrži recirkulacijski ventil (78) koji olakšava punjenje pumpe 1 za održavanje razvodnika i spremnika za napajanje tekućinom kod tlaka okoline tijekom rada.
The combined filtrate was heated to 72°C to redissolve the material, then adjusted to 50°C. The solution was seeded with 3-phenylsulfonyl-8-piperazin-1-yl-quinoline (Form III) (10mg), cooled to 35°C over 30 minutes, held for 1 hour, then cooled to 20°C over 30 minutes, and stirred for a further 48 hours. 
Pomiješani filtrat grije se do 72 *C kako bi se ponovno otopilo the materijal, te podesi na 50 "C. Otopinu se zasije 3-fenilsulfonil-8-piperazin-1-ilkinolinom (Oblik III) (10 mg), 30 minuta hladi do 35 "€, održava 1 sat, 30 minuta hladi do 20 "C, te miješa još 48 sati.
For a formulation with a concentration of 4.0 mg/mL, 800 mg of NaCl is dissolved in 80 mL of water, then 57.5 µL of glacial acetic acid is added, followed by 512 mg of the dihydrogenphosphate salt monohydrate. 
Za formulaciju sa koncentracijom od 4.0 mg/mL, 800 mg NaCI je otopljeno u 80 mL vode, zatim je dodano 57.5 ledene octene kiseline, praćeno sa 512 mg monohidrata dihidrogenfosfatne soli.
A closure for a vial or a plunger for a hypodermic syringe according to claim 1 which comprises Cawiton™ PR5947, compounded with 3 - 15 wt% of a colourant masterbatch comprising an LDPE carrier with 15 - 20 wt% of pigment of a colour Pantone 5497C, 556C, 5565C, 563C, 570C, 555C. 
Zatvarač za bočicu ili klip za potkožnu špricu u skladu s patentnim zahtjevom 1, koji sadržava CawitonTM PR5947, koji je pomiješan s 3 - 15 masenih % glavne šarže sa sredstvom za bojenje koja sadržava LDPE kao nosilac s 15 20 masenih % pigmenta boje Pantone 5497C, 556C, 5565C, 563C, 570C ili 555C.
The compounds of Set B are meant to further illustrate the scope of the invention without being limiting in any way. 
Spojevi Skupine B namjeravaju dalje opisati doseg izuma bez njegovog ograničavanja na bilo koji način.
In order to separate the isomers, the mixture is treated with R (+) Mosher's acid, in the presence of oxalyl chloride and dimethylaminopyridine (DMAP) in dichloromethane to give a pair of diastereoisomeric esters (VII) (of which only one diastereoisomer is shown) which can then be separated using HPLC. 
Da bi se odijelili izomeri, smjesa se tretira sa R (+) Mosher-ovom kiselinom u prisutnosti oksalil klorida 1 dimetilaminopiridina (DMAP) u diklorometanu dajući par dijastereoizomernih estera (VII) (od kojih je prikazan samo jedan dijastereoizomer) koji se mogu odijeliti uporabom HPLC.
According to one embodiment, the housing is cylindrical, having a cylindrical inner surface, and the valve member is cylindrical, having a cylindrical outer surface According to one embodiment, the valve member is rotatably arranged in the housing. 
Ventil prema patentnom zahtjevu 1, gdje je navedeno kućište (102) cilindrično, ima cilindričnu unutarnju površinu (112), i navedeni ventilski element (104) je cilindričan, i ima cilindričnu vanjsku površinu (144).
A fumarate salt of compound (I) represented by the following structural formula: 
Maleat sol spoja (I) je predstavljena slijedećom strukturnom formulom:
A microencapsulated bacterial consortium, characterized in that it comprises: (a) three different strains of commercially available lactic-acid bacteria; b) encapsulating agents; c) prebiotics; and d) trehalose; in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin. 
Mikroenkapsulirani bakterijski konzorcij, naznačen time što sadrži: (a) tri različita soja komercijalno dostupnih bakterija mliječne kiseline; b) agense za enkapsulaciju; c) prebiotike; 1 d) trehalozu; u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla.
A solid form of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide, which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Ka radiation, expressed in degrees 2θ) at approximately 5.5, 10.9, 14.2, 21.9 and 24.0. 
Čvrsti oblik 1-(2-metil-4-(2,3,4,5-tetrahidro-1-benzazepin-1-ilkarboml)benzilkarbamoil)-1-prolin-N,N-dimetilamida, koji pokazuje najmanje slijedeće karakteristične XRF pikove difrakcije praha (Cu Ko. zračenje, izraženo u stupnjevima 20) na približno 5.5, 10.9, 14.2, 21.9 124.0.
The ground engaging apparatus (10) of Claim 7 further comprising cooperatively engageable abutment structures carried by said longitudinally central portion of said connector pin member (34) and said hollow body and being operable to limit the total amount of relative rotation between said connector pin member and said hollow body. 
kooperativno surađujuće granične strukture nošene od strane navedenog uzdužnog centralnog dijela navedenog elementa (34) spojnog klina i navedenog šupljeg tijela koje se mogu koristiti da bi se ograničila ukupna količina relativne rotacije između navedenog elementa (34) spojnog klina i navedenog šupljeg tijela.
A process of preparing the hydrate of claim 2, comprising: reacting a first mixture comprising 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and water with at least two equivalents of hydrochloric acid in a solvent comprising water to form a second mixture; and 
Postupak za pripremanje hidrata prema zahtjevu 2, naznačen time da sadrži: a) reakciju prve smjese koja sadrži 2-fluoro-N-metil-4-[7-(kinolin-6-ilmetil)jimidazo[1,2-b][1,2,4]triazin-2- illbenzamid i vodu s barem dva ekvivalenta klorovodične kiseline u otapalu koje sadrži vodu tako da nastane druga smjesa; i b) miješanje druge smjese s metil tert-butil eterom.
The formulation according to claim 4, in the form of tablets. 
Formulacija u skladu sa patentnim zahtjevom 3, u obliku tableta.
the antisense oligomer which has a nucleotide sequence having at least 80% identity with a nucleotide sequence of SEQ ID NO: 1 or 2 and has an activity to cause skipping of the 51st exon in the human dystrophin gene. 
antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 80% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 i ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
and R2 are as defined above, R3 is H or COCH3; with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the -ONO2 group is bound to -(CH2)n1; 
i R2 jesu kao što su gore definirani, R3 je H ili –COCH3, s ograničenjem da kada je Y odabran od dvovalentnih radikala spomenutih pod b)-f), –ONO2 skupina je vezana za –(CH2)n1,
Also within the scope of the invention are pharmaceutical formulations that include any of the aforementioned compositions in addition to a pharmaceutically acceptable carrier or diluent. Pharmaceutical formulations of the invention will include at least one therapeutic agent. 
Farmaceutska formulacija koja uključuje spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4 ili spoj u skladu s patentnim zahtjevom 5, farmaceutski prihvatljiv nosač ili razrjeđivač i najmanje jedan terapijski agens.
The method of claim 1, wherein the ciclesonide or the pharmaceutically acceptable salt thereof or the composition comprising ciclesonide or the pharmaceutically acceptable salt thereof is a partially ethanolic formulation and is administered to the equine via an inhaler device. The method of claim 13, wherein the ciclesonide or the pharmaceutically acceptable salt thereof or the composition comprising ciclesonide or the pharmaceutically acceptable salt thereof is administered to the equine at a dose selected from the group consisting of: at least 900 ug ex inhaler, at least 1800 ug ex inhaler, at least 2700 ug ex inhaler, and at least 2700 ug ex inhaler. 
Ciklezonid ili njegova farmaceutski prihvatljiva sol ili pripravak koji sadrži ciklezonid ili njegovu farmaceutski prihvatljivu sol prema zahtjevima od 1 do 10, naznačen time, da je za uporabu u postupku kod liječenja bolesti dišnih puteva kod Equinae, poželjno konja, gdje se navedeni ciklezonid ili navedena njegova farmaceutski prihvatljiva sol ili navedeni pripravak koji sadrži ciklezonid ili navedenu njegovu farmaceutski prihvatljivu sol, primjenjuje u dozi od najmanje 900 ug iz inhalatora, najmanje 1800 ug iz inhalatora, najmanje 2400 ug iz inhalatora, ili najmanje 2700 ug iz inhalatora, poželjno najmanje 2700 ug iz inhalatora.
640 mg of the crude are suspended in 25 mL of hexane, filtered, and washed with 7.5 mL of chloroform, obtaining 450 mg of the product (5) with a purity of 99.7% by HPLC. 
640 mg sirovog proizvoda se suspendira u 25 mL heksana, profiltrira 1 ispere sa 7,5 mL kloroforma, čime se dobije 450 mg proizvoda (5) čistoće 99,7% pomoću HPLC.
Castration results in elevated levels of circulating LH due to reduction of the negative feedback of gonadal steroids resulting in enhancement of GnRH stimulated LH release. 
Kastriranje uzrokuje porast razine LH u krvotoku zbog oslabljene negativne povratne veze gonadnih steroida, što uzrokuje pojačano otpuštanje LH stimulirano GnRH-om.
The mixture was poured on to a stirred mixture of crushed ice (112 g), water (56 ml) and glacial acetic acid (12.2 g). 
Smjesa se ulije u miješanu smjesu smrvljenog leda (112 g), vode (56 ml) 1 glacijalne octene kiseline (12.2 g).
The infrared spectrum of the solid product was recorded using a Nicolet Avatar 360 FT-IR spectrometer fitted with a universal ATR accessory. 
Infracrveni spektar za čvrsti produkt zabilježen je spektrometrom Nicolet Avatar 360 FT-IR, opremljenim univerzalnim ATR dodatkom.
(b3.5) sealing the top opening of the cup-shaped body with a gas- impermeable film, said film being a multilayer comprising a first layer made of aluminum and a second layer made of polypropylene. 
(b3.5) brtvljenje gornjeg otvora kućišta u obliku čašice filmom nepropusnim za plin, pri čemu navedeni film ima više slojeva i sadržava prvi sloj aluminija i drugi sloj polipropilena.
means (709-L1) for frequency-interleaving the time-interleaved preamble data symbols; means (711) for building a signal frame based on the frequency-interleaved preamble data symbols and the frequency-interleaved service data symbols; 
sredstvo (711) za izgradnju okvira signala na temelju simbola podataka početnog niza s umetnutim vremenom i simbola servisnih podataka s umetnutim vremenom;
Sealing means 41, 42, such as, for example, rubber strips, can be fitted on the flanges 34, 35 of the part 31 of the rigid line section 32. 
Sredstvo za brtvljenje 41, 42, kao, na primjer, gumene trake, se mogu pričvrstiti na prirubnice 34, 35 dijela 31 čvrstog dijela cijevi 32.
The r-hTBP-1-producing cell line was generated by transfecting CHO-DUKX cells with a vector comprising a cDNA encoding r-hTBP-1 and appropriate expression elements. 
Stanična linija koja proizvodi r-hTBP-1 bila je dobivena s pomoću transfekcije stanica CHO-DUKX s vektorom koji sadrži cDNA koja kodira r-hTBP-1 te odgovarajuće ekspresijske elemente.
The compound of claim 1 or a salt, isomer or polymorph thereof, wherein R3 is-C(O)-NH-Z3(R10); X3 is absent; Z3 is absent or alkyl; and, R10 is C3-C12 cycloalkyl optionally substituted by one or more alkyl or carbonylalkoxy. 
Spoj u skladu sa zahtjevom 1 ili njegova sol, izomer ili polimorf, naznačen time, da R3 je -C(O)-NH-Z3(R10); X3 je odsutan; Z3 je odsutan ili alkil; te R10 je C3-C12 cikloalkil po izboru supstituiran s jednim ili više alkil ili karbonilalkoksi.
The aqueous formulation of claim 1 or 2 comprising 0.1 µg to 10 µg lixisenatide per U insulin glargine, preferably 0.2 to 1 µg lixisenatide per U insulin glargine, and more preferably 0.25 µg to 0.7 µg lixisenatide per U insulin glargine. 
Vodena formulacija prema zahtjevu 1 ili 2 naznačena time da sadrži 0.1 µg do 10 µg liksisenatida po jedinici inzulin glargina, poželjno 0.2 do 1 µg liksisenatida po jedinici inzulin glargina, i more poželjno 0.25 µg do 0.7 µg liksisenatida po jedinici inzulin glargina.
mixing a compound represented by formula (B): 
(a) miješanje spoja predstavljenog formulom (B): iPormula 1]
A combination of at least one sigma ligand as defined in any of claims 1 to 3 and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for use in the prevention and/or treatment of pain associated to bone cancer. 
Kombinacija najmanje jednog sigma liganda u skladu s bilo kojim od patentnih zahtjeva 1 do 3 s najmanje jednim opioidnim ili opijatnim spojem, namijenjena istodobnom, odvojenom ili uzastopnoj primjeni, naznačena time što je namijenjena upotrebi u sprječavanju i/ili liječenju boli povezane s rakom kostiju.
Preferred example of a compound of the formula: 
Broj objave europskog patenta:
Ring A is a 5-membered carbocyclic ring or a 5-membered heterocyclic ring optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, C1-4 alkyl, C1-4 alkoxy and C3-5 cycloalkyl; or 
Prsten A je 5-člani karbociklički prsten ili 5-člani heterociklički prsten po izboru supstituiran sa 1 do 4 supstituenda izabrana iz skupine koju čine: halogen, Ci4 alkil, C,.4 alkoksi, te
The method of claim 1, wherein the solid form has a thermal gravimetric analysis plot comprising a mass loss of less than approximately 0.5% when heated from approximately 25° C. to approximately 150° C. 
Čvrsti oblik u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što ima grafički prikaz toplinske gravimetrijske analize koji sadrži gubitak mase manji od otprilike 0,5% prilikom grijanja od otprilike 25%C€ do otprilike 150*C.
The minimally invasive skin treatment device of claim 1, wherein the tool comprises an injection device and a nozzle (1506), wherein the nozzle is configured to discharge a fluid in a direction parallel to the top of the handpiece and configured to increase a kinetic energy of the fluid when the fluid is injected by the injection device through the nozzle. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 1, naznačen time, da alat obuhvaća napravu za ubrizgavanje i mlaznicu (1506), pri čemu je mlaznica konfigurirana za ispuštanje fluida u smjeru paralelnom s vrhom ručnog kompleta 1 oblikovana tako da povećava kinetičku energiju fluida kada se uštrcava tekućina kroz napravu za uštrcavanje kroz mlaznicu.
The process according to claim 15, wherein the addition of the solution of the gadobenate dimeglumine to the antisolvent B is performed in a time of from 2 to 6 hours. 
Postupak prema zahtjevu 15 naznačen time što se dodavanje otopine gadobenat dimeglumina u protuotapalo B provodi u vremenu od 2 do 6 sati.
Hungarian patent specification No. 
mađarska patentna specifikacija br.
Thus, in a preferred embodiment, the present light stabilising composition is derived from a caramelised feedstock and combines a relatively high absorption of UV light, particularly at wavelengths in the range of 250 to 400 nm, with a relatively low absorption of visible light, as demonstrated by a ratio of the light absorption at wavelengths 280 nm and 560 nm (A280/560) of at least 80, preferably of at least 250. 
Dakle, u poželjnom ostvarenju, sadašnji pripravak za stabiliziranje na svjetlo se dobiva iz karamelizirane sirovine i sjedinjuje relativno visoku apsorpciju UV svjetla, naročito pri valnim duljinama u opsegu od 250 do 400 nm, uz relativno nisku apsorpciju vidljivog svjetla, što se prikazuje omjerom apsorpcije svjetla na valnim duljinama 280 nm i 560 nm (A280;560) od najmanje 80, poželjno od najmanje 250.
Iota-carrageenan for use as claimed in any one of claims 1 to 3, wherein the antiviral pharmaceutical composition or medicament is adapted for oral administration and is preferably prepared as a liquid solution, or as a semi-solid or solid preparation such as a dry powder, tablets, capsules, or dragees. 
Jota-karagenan namijenjen upotrebi u skladu s bilo kojim od patentni zahtjeva 1 do 3, naznačen time što je antivirusni farmaceutski pripravak ili medikament prilagođen za oralnu primjenu i po mogućnosti se pripravlja u obliku tekuće otopine, ili u obliku polučvrstog ili čvrstog pripravka, primjerice u obliku suhog praha, tableta, kapsula ili dražeja.
The instrument according to claim 5, wherein the suturing device is adapted to suture the open end of the cup like portion of the fundus wall before the movement restriction device is inserted by the insertion device through the hole in the fundus wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što je uređaj prilagođen da bude u najmanju ruku djelomično invaginiran u stijenku želuca međuželučanim kopčama, s vanjske strane stijenke želuca.
The invention relates to a monoclonal antibody, or a divalent functional fragment or derivative thereof, capable to inhibit the c-Met dimerization and comprising a heavy chain comprising CDR-H1, CDR-H2 and CDR-H3 with respectively the amino acid sequences SEQ ID Nos. 1, 2 and 3 or a sequence having at least 80% identity after optimum alignment with sequences SEQ ID Nos. 1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with respectively the amino acid sequences SEQ ID Nos. 5, 6 and 7 or a sequence having at least 80% identity after optimum alignment with sequences SEQ ID Nos. 5, 6 or 7, said antibody being further characterized in that it also comprises a hinge region comprising the amino acid sequence SEQ ID No. 56. 
HR P20181868 T1 PATENTNI ZAHTJEVI Monoklonalno antitijelo, ili njegov dvovalentni funkcionalni fragment, koji može inhibirati dimerizaciju c-Met, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, sadrži teški lanac koji sadrži CDR-H1, CDR-H2 te CDR-H3 s aminokiselinskim sekvencijama SEQ ID Nos. 1, 2 1 3; te laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 s aminokiselinskim sekvencijama SEQ ID Nos. 5, 6 1 7, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, dalje naznačeno time da: i)
In some embodiments, the genotype of the E. coli lacks degP and prc genes and harbors a mutant spr gene. 
Postupak prema zahtjevima 5 ili 6, naznačen time, da genotipu bakterije £. coli nedostaju geni degP i prc, ali uzgaja mutirajući gen spr.
A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof as claimed in claims 1 to 4, and a pharmaceutically acceptable adjuvant, diluent or carrier. 
Farmaceutski pripravak koji sadrži spoj formule (I), ili neka njegova farmaceutski prihvatljiva sol prema zahtjevima 1 do 4, te neki farmaceutski prihvatljivi adjuvant, razrjeđivač ili nosač.
A compound as defined in claim 1 or claim 2 wherein A represents a phenyl group optionally substituted by one or more Ra groups. 
Spoj prema zahtjevu 1 ili zahtjevu 2, pri čemu A predstavlja fenil grupu opcionalno supstituiranu sa jednom ili više Ra grupa.
Equisetum hiemale in form of plant or part of plant, juice, dry extract, hydro alcoholic extract or glycolic extract 
- = Equisetum hiemale u obliku biljke ili dijela biljke, soka, suhog ekstrakta, hidro alkoholnog ekstrakta ili glikolnog ekstrakta
The method according to claim 1, wherein said effective amount is about 0.001-50 mg/kilogram of said animal. The method according to claim 1, wherein said administering is by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intraarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intrapelvic, intraperitoneal, intrapleural, intrapulmonary, intrasynovial, intrathoracic, intralesional, bolus, intranasal, and transdermal. 
Predmet proizvodnje prema patentnom zahtjevu 19, gdje je spomenuta posuda komponenta parenteralnog, subkutanog, - intramuskularnog, = intravenoznog, = intraartikularnog, = intrabronhijalnog, = intraabdominalnog, intrakapsularnog, intrahrskavičavog, intrakavitalnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastričnog, intrahepatičkog, intramiokardialnog, intraostealnog, intrakarličnog, intraperikardialnog, intraperitonalnog, intrapleuralnog, intraprostatičnog, intrapulmonalnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog, intrasinovijalnog, intratorakalnog, intrauterinog, intravezikalnog, intralezionalnog, u bolusu, vaginalnog, rektalnog, bukalnog, sublingvalnog, intranazalnog, ili transdermalnog uređaja za davanje, ili sistema.
The use or compound for use according to any one of claims 1 to 4, wherein the medicament comprises one or more pharmaceutically acceptable excipients. 
Jedinični dozirni oblik za uporabu prema zahtjevima 1 do 4, koji dalje sadrži jednu ili više farmaceutski prikladnih pomoćnih tvari.
Bottling was performed in such a way that entrapment of atmospheric oxygen in the beer and headspace was minimised. 
Flaširanje se provede na takav način, da se minimizira količina zarobljenog atmosferskog kisika u pivu i prostoru iznad.
The method of claim 5, wherein the sequences that align to the first chromosome are selected to be less than a specified number of base pairs. 
Postupak prema zahtjevu 3, naznačen time, da su sekvence koje imaju podrijetlo iz prvog kromosoma, odabrane tako, da budu manje nego što je specifični broj temeljnih parova.
Preferred embodiments of the smoking article according to the present invention are described in greater detail in the accompanying drawings and in the detailed description of the invention which follow. 
Cigaretni substitut iz sadašnjeg izuma opisan je detaljnije na pratećim crtežima 1 u detaljnijem opisu izuma koji slijedi.
Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center. 
Mogu se formirati odgovarajuće soli uz dodatak kiseline, ako se želi, ako imaju dodatni prisutni bazični centar.